Computational and Structural Chemistry, Merck & Co., Inc., West Point, PA, USA.
Quantitative Biosciences, Merck & Co., Inc., West Point, PA, USA.
Nat Commun. 2021 May 24;12(1):3040. doi: 10.1038/s41467-021-23312-8.
All herpesviruses encode a conserved DNA polymerase that is required for viral genome replication and serves as an important therapeutic target. Currently available herpesvirus therapies include nucleoside and non-nucleoside inhibitors (NNI) that target the DNA-bound state of herpesvirus polymerase and block replication. Here we report the ternary complex crystal structure of Herpes Simplex Virus 1 DNA polymerase bound to DNA and a 4-oxo-dihydroquinoline NNI, PNU-183792 (PNU), at 3.5 Å resolution. PNU bound at the polymerase active site, displacing the template strand and inducing a conformational shift of the fingers domain into an open state. These results demonstrate that PNU inhibits replication by blocking association of dNTP and stalling the enzyme in a catalytically incompetent conformation, ultimately acting as a nucleotide competing inhibitor (NCI). Sequence conservation of the NCI binding pocket further explains broad-spectrum activity while a direct interaction between PNU and residue V823 rationalizes why mutations at this position result in loss of inhibition.
所有疱疹病毒都编码一种保守的 DNA 聚合酶,该酶是病毒基因组复制所必需的,也是一个重要的治疗靶点。目前可用的疱疹病毒疗法包括核苷和非核苷抑制剂(NNI),它们靶向疱疹病毒聚合酶的 DNA 结合状态并阻断复制。在这里,我们报告了单纯疱疹病毒 1 聚合酶与 DNA 以及 4-氧代-二氢喹啉 NNI(PNU-183792)的三元复合物晶体结构,分辨率为 3.5Å。PNU 结合在聚合酶的活性部位,取代模板链并诱导手指结构域发生构象变化,进入开放状态。这些结果表明,PNU 通过阻止 dNTP 的结合并使酶处于无催化能力的构象而抑制复制,最终作为核苷酸竞争抑制剂(NCI)发挥作用。NCI 结合口袋的序列保守性进一步解释了广谱活性,而 PNU 与残基 V823 之间的直接相互作用解释了为什么该位置的突变会导致抑制作用丧失。